Categories
Cancer Care (474)
I-CARE Early Covid (187)
I-CARE Flu and RSV (36)
I-PREVENT (153)
I-RECOVER Long Covid (111)
I-RECOVER Post-Vaccine (320)
MATH+ (288)
Tags
ACE2 protein (10)
acute respiratory distress syndrome (21)
Anti-inflammatory (13)
Antidepressants (9)
Ascorbic Acid (13)
autoantibodies (10)
autophagy (48)
Breast Cancer (30)
Cancer (69)
Cancer Stem Cells (11)
Chemotherapy (12)
Colon Cancer (11)
Corticosteroids (9)
COVID-19 (330)
COVID-19 Vaccines (8)
Curcumin (14)
Cytokines (13)
Depression (12)
Diabetes (14)
Famotidine (14)
Hydroxychloroquine (15)
Hyperbaric Oxygen Therapy (9)
Inflammation (15)
intermittent fasting (14)
ivermectin (53)
long COVID (21)
Macrophages (18)
Mast Cells (8)
Melatonin (23)
Mitochondria (14)
Myeloid Cells (10)
Pneumonia (9)
quercetin (15)
resveratrol (11)
SARS-CoV-2 (83)
Sepsis (22)
spermidine (11)
Spike Protein (12)
Thiamine (11)
Thrombosis (9)
Tinnitus (12)
Tumor (41)
Vitamin C (30)
Vitamin D (29)
Zinc (12)
Reference: A raising dawn of pentoxifylline in the management of inflammatory disorders in Covid-19.
Authors: Mostafa-Hedeab G, Al-kuraishy HM, Al-Gareeb AA, Jeandet P, Saaad HM, El-Saber Batiha G PMID: 35486310 PMCID: PMC9051499 DOI: 10.1007/s10787-022-00993-1 Abstract The existing pandemic viral infection caused by severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) leads to coronavirus disease 2019 (Covid-19). SARS-CoV-2 exploits angiotensin-converting enzyme 2 (ACE2) as an entry-point into affected cells and [...]
Categories: I-RECOVER Long Covid, I-RECOVER Post-Vaccine
Tags: COVID-19, Pentoxifylline
